O IBC Lisbon 2021 trata-se um evento com um programa científico internacional, com a duração de dois dias e que visa fornecer informações de última geração sobre o câncer de mama, fomentando o equilíbrio entre a investigação clínica, translacional e básica, bem como, proporcionar um fórum de interação, discussão e aprendizagem para médicos e farmacêuticos hospitalares e outros especialistas (profissionais de saúde e investigadores) com especial interesse no câncer de mama. Data: de 14/10/2021 a 15/10/2021Local: OnlineEndereço: Lisboa, PortugalInvestimento/Taxa de Inscrição: 350€ (IVA incluído)Inscrições: http://www.innovationinbreastcancer.com/lisbon
In this annual multidisciplinary meeting, attended by all professionals related to breast cancer, a comprehensive review of the advances in research, diagnosis and treatment of this disease is carried out.The main objective of this event is to become the reference for all those interested in knowing in an independent, complete and critical way the advances in breast cancer. The event will take place on June 17th and 18th in a virtual format. Sign up on the website:: https://www.ragmageicam.org/ Check out the event schedule
Evento em formato virtual contará com palestrantes nacionais e internacionais em sua programação para discutir os principais avanços no diagnóstico e tratamento do câncer de mama. Entre os dias 9 e 11 de março de 2021, se realizará a Conferência Brasileira de Câncer de Mama 2021, e o evento oficial licenciado Best of SABCS Brazil. Este evento é organizado pelo Latin American Cooperative Oncology Group (LACOG) e Grupo Brasileiro de Estudos em Câncer de Mama (GBECAM), instituições brasileiras dedicadas à educação e pesquisa em câncer de mama. O evento deste ano será em formato virtual e reunirá especialistas nacionais e internacionais para debater os principais avanços no diagnóstico e tratamento do câncer de mama. O primeiro dia do evento será dedicado ao Best of SABCS Brazil, no qual os participantes poderão acompanhar o que foi destaque no San Antonio Breast Cancer Symposium – realizado em dezembro de 2020, nos Estados Unidos. O SABCS é um dos mais relevantes congressos mundiais que debate pesquisa básica, translacional e clínica em câncer de mama. Os principais temas abordados no encontro serão agora apresentados e discutidos com exclusividade no Brasil. Nos outros dias do evento teremos módulos dedicados ao tratamento de doença inicial e metastática apresentando
The results of the PALLAS study, which evaluated the addition of Palbociclib to adjuvant endocrine therapy in breast cancer, were presented at the ESMOVirtual Congress 2020 on September 20, 2020.The PALLAS study was conducted by the Austrian Breast and Colorectal Cancer Study Group (ABCSG), Austria and the ALLIANCE Foundation Trials group - United States. LACOG participated in the study as part of a collaborative group working in Latin America along with Mexican research centers that made a significant contribution to the study.
GEICAM started this initiative in 2008 with the purpose of presenting an in-depth review of the most relevant milestones presented at congresses and international publications annually. At this annual multidisciplinary meeting, attended by all professional involved with breast cancer, a comprehensive review of the advances made in research, diagnosis and treatment in connection with this disease has been carried out. The main goal of this event is to become a reference for everyone interested in finding out more about the advances made in terms of breast cancer in an independent, comprehensive and critical fashion. Sign up at: https://www.ragmageicam.org/ and participate!
The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115)
Members of LACOG Breast cancer group have recently published the article “The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115)” AMAZONA III/ GBECAM 0115 is a prospective cohort study that evaluated Brazilian patients with newly diagnosed breast cancer from 2016 to 2018. This manuscript depicts a wide and detailed scenario of sociodemographic characteristics of 2,950 breast cancer patients at diagnosis. The patients were from 23 sites in Brazil. The results of the study show that patients with public health coverage were diagnosed with symptomatic disease, at later stages and with more aggressive subtypes of breast cancer when compared to patients with private health coverage. This study brings to light important information that allows us to not only have a better understanding of tumor and patients’ characteristics but also, help to identify gaps within healthcare systems in Brazil. With such knowledge, it’s possible to develop strategies to improve screening and educational programs in the country, especially in the public setting.